Pauly D F, Fraites T J, Toma C, Bayes H S, Huie M L, Hirschhorn R, Plotz P H, Raben N, Kessler P D, Byrne B J
Peter Belfer Cardiac Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Hum Gene Ther. 2001 Mar 20;12(5):527-38. doi: 10.1089/104303401300042447.
Pompe disease is a lethal cardioskeletal myopathy in infants and results from genetic deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). Genetic replacement of the cDNA for human GAA (hGAA) is one potential therapeutic approach. Three months after a single intramuscular injection of 10(8) plaque-forming units (PFU) of E1-deleted adenovirus encoding human GAA (Ad-hGAA), the activity in whole muscle lysates of immunodeficient mice is increased to 20 times the native level. Direct transduction of a target muscle, however, may not correct all deficient cells. Therefore, the amount of enzyme that can be transferred to deficient cells from virally transduced cells was studied. Fibroblasts from an affected patient were transduced with AdhGAA, washed, and plated on transwell culture dishes to serve as donors of recombinant enzyme. Deficient fibroblasts were plated as acceptor cells, and were separated from the donor monolayer by a 22-microm pore size filter. Enzymatic and Western analyses demonstrate secretion of the 110-kDa precursor form of hGAA from the donor cells into the culture medium. This recombinant, 110-kDa species reaches the acceptor cells, where it can be taken up by mannose 6-phosphate receptor-mediated endocytosis. It then trafficks to lysosomes, where Western analysis shows proteolytic processing to the 76- and 70-kDa lysosomal forms of the enzyme. Patient fibroblasts receiving recombinant hGAA by this transfer mechanism reach levels of enzyme activity that are comparable to normal human fibroblasts. Skeletal muscle cell cultures from an affected patient were also transduced with Ad-hGAA. Recombinant hGAA is identified in a lysosomal location in these muscle cells by immunocytochemistry, and enzyme activity is transferred to deficient skeletal muscle cells grown in coculture. Transfer of the precursor protein between muscle cells again occurs via mannose 6-phosphate receptors, as evidenced by competitive inhibition with 5 mM mannose 6-phosphate. In vivo studies in GAA-knockout mice demonstrate that hepatic transduction with adenovirus encoding either murine or human GAA can provide a depot of recombinant enzyme that is available to heart and skeletal muscle through this mechanism. Taken together, these data show that the mannose 6-phosphate receptor pathway provides a useful strategy for cell-to-cell distribution of virally derived recombinant GAA.
庞贝氏病是一种发生于婴儿的致死性心脏骨骼肌病,由溶酶体酶酸性α-葡萄糖苷酶(GAA)的基因缺陷所致。对人GAA(hGAA)的cDNA进行基因替代是一种潜在的治疗方法。单次肌肉注射10⁸ 个空斑形成单位(PFU)编码人GAA的E1缺失腺病毒(Ad-hGAA)三个月后,免疫缺陷小鼠全肌肉裂解物中的活性增加至天然水平的20倍。然而,直接转导靶肌肉可能无法纠正所有缺陷细胞。因此,研究了从病毒转导细胞转移至缺陷细胞的酶量。用AdhGAA转导一名患病患者的成纤维细胞,洗涤后接种于Transwell培养皿上作为重组酶的供体。将缺陷成纤维细胞作为受体细胞接种,并通过22微米孔径的滤膜与供体单层细胞隔开。酶学和蛋白质印迹分析表明,110 kDa的hGAA前体形式从供体细胞分泌到培养基中。这种重组的110 kDa蛋白到达受体细胞,在那里它可以通过甘露糖6-磷酸受体介导的内吞作用被摄取。然后它转运至溶酶体,蛋白质印迹分析显示在溶酶体中该酶被蛋白水解加工成76 kDa和70 kDa的溶酶体形式。通过这种转移机制接受重组hGAA的患者成纤维细胞达到了与正常人成纤维细胞相当的酶活性水平。也用Ad-hGAA转导一名患病患者的骨骼肌细胞培养物。通过免疫细胞化学在这些肌肉细胞的溶酶体位置鉴定出重组hGAA,并且酶活性转移至共培养的缺陷骨骼肌细胞。5 mM甘露糖6-磷酸的竞争性抑制证明,前体蛋白在肌肉细胞之间的转移同样通过甘露糖6-磷酸受体发生。在GAA基因敲除小鼠中的体内研究表明,用编码小鼠或人GAA的腺病毒进行肝脏转导可以提供一个重组酶储存库,该储存库可通过这种机制供心脏和骨骼肌利用。综上所述,这些数据表明甘露糖6-磷酸受体途径为病毒衍生的重组GAA的细胞间分布提供了一种有用的策略。